Servier discontinues CD19 development; Allogene may exercise ex-US license at added cost

Allogene Therapeutics, Inc.

Servier sent discontinuation notice for CD19 products (UCART19, ALLO-501, ALLO-501A) per Servier Agreement.
Allogene can elect ex-US license; if exercised, milestone payments for ALLO-501A increase by €46M aggregate.
Allogene's right to recover 40% of development costs from Servier would cease upon exercise of ex-US option.
Servier requested Allogene exercise option within limited timeframe; Cellectis challenges sublicense rights, adding legal risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.